ALKS:NSD-Alkermes Plc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 22.32

Change

0.00 (0.00)%

Market Cap

USD 3.67B

Volume

1.11M

Avg Analyst Target

USD 30.33 (+35.90%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ALKS Stock Forecast & Price:
Based on the Alkermes Plc stock forecasts from 5 analysts, the average analyst target price for Alkermes Plc is USD 30.33 over the next 12 months. Alkermes Plc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Alkermes Plc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Alkermes Plc’s stock price was USD 22.32. Alkermes Plc’s stock price has changed by -4.49% over the past week, -11.46% over the past month and -30.42% over the last year.

About Alkermes Plc (ALKS:NSD)

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intra ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-24 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
PPD PPD Inc

N/A

USD16.61B 47.04 21.58
VTRS Viatris Inc

N/A

USD10.84B 14.19 6.61
NBIX Neurocrine Biosciences Inc

N/A

USD10.10B 812.54 215.33
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
LNTH Lantheus Holdings Inc

N/A

USD4.83B 175.65 46.18
ITCI Intracellular Th

N/A

USD4.18B N/A -12.06
EVO Evotec SE ADR

N/A

USD3.25B 458.50 69.28
PCRX Pacira Pharmaceuticals Inc

N/A

USD2.47B 66.60 21.63

ETFs Containing ALKS

Symbol Name Weight Mer Price(Change) Market Cap
SBIO ALPS Medical Breakthrough.. 0.00 % 0.50 %

N/A

USD0.11B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.04% 81% B- 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.04% 81% B- 73% C
Trailing 12 Months  
Capital Gain -30.42% 73% C 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.42% 73% C 49% F
Trailing 5 Years  
Capital Gain -56.89% 62% D- 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -56.89% 60% D- 20% F
Average Annual (5 Year Horizon)  
Capital Gain -6.88% 53% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.88% 53% F 27% F
Risk Return Profile  
Volatility (Standard Deviation) 38.58% 56% F 40% F
Risk Adjusted Return -17.84% 57% F 37% F
Market Capitalization 3.67B 96% A 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.55 24% F 24% F
Price / Cash Flow Ratio 36.04 8% F 7% F
EV/EBITDA -231.07 98% A+ 97% A+
Management Effectiveness  
Return on Equity -8.64% 71% C- 49% F
Return on Invested Capital -2.77% 67% D+ 46% F
Return on Assets -2.51% 68% D+ 44% F
Debt to Equity Ratio 26.32% 55% F 53% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 5.89 24% F 25% F
Short Percent 6.69% 30% F 23% F
Beta 0.61 75% C 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector